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agents. In particular, the claim is made that the benefits of ramipril
and perindopril evidenced in the HOPE (Heart Outcomes Pre-
vention Evaluation) (2), and EUROPA (EURopean trial On
reduction of cardiac events with Perindopril in stable coronary
Artery disease) (3) trials, respectively, are due to the lower BP
levels achieved by these agents in the treated groups. However,
when a similarly decreased level of BP is achieved in the
trandolapril-treated group in the PEACE (Prevention of Events
with Angiotensin Converting Enzyme inhibition) (4) trial, no
cardiovascular outcomes benefit is observed.
Does not this dichotomy denigrate the concept that only the
achieved BP level is what matters? Do the results of these three
trials suggest that perhaps differences exist among angiotensin-
converting enzyme inhibitors beyond their additive BP effects?
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REPLY
In a previous review, I stated that the data from large-scale clinical
trials of the treatment of hypertension suggested that the main
driver of benefit from blood-pressure (BP) lowering drugs was the
BP lowering per se (1). Dr. Schwartz in his response to this review
notes that, although the HOPE (Heart Outcomes Prevention
Evaluation) (2) and EUROPA (EURopean trial On reduction of
cardiac events with Perindopril in stable coronary Artery disease)
(3) studies showed benefits of angiotensin-converting enzyme
(ACE) inhibition versus placebo in reducing cardiovascular events
in patients with cardiovascular disease, the more recent PEACE
(Prevention of Events with Angiotensin Converting Enzyme
inhibition) (4) study did not. Dr. Schwartz states that this
dichotomy might suggest within-drug-class differences, pointing
to the benefit of specific ACE inhibitors “beyond blood pressure.”
This concept is tenuous at best and could only be proven by testing
different ACE inhibitors head-to-head in the same patient popu-
lation.
The differences in outcomes when comparing the HOPE and
EUROPA trials with the PEACE trial reflect different patient
populations and differences in comcomitant medications. Com-
pared to the HOPE and EUROPA trials, the the PEACE trial
cohort was more aggressively treated with lipid-lowering drugs
(70%), antiplatelet drugs (90%), and beta-blockers (60%), and in
such an aggressively treated population it was not even possible to
show an additional benefit of the ACE inhibitor-induced BP
lowering. The message from the PEACE study was admirably
summed up by the investigators: “in a population of patients with
coronary artery disease and preserved ejection fraction who receive
intensive current standard therapy . . . , there appears to be no
evidence of cardiovascular benefit from the addition of ACE-
inhibitor therapy” (4).
With regard to treating hypertension in an endeavor to prevent
the development of fatal or nonfatal myocardial infarction (MI),
the ALLHAT (Antihypertensive and Lipid Lowering treatment
to prevent Heart Attack Trial) study tested this hypothesis and
failed to show an advantage of ACE inhibition (5). Moreover, the
more recent CAMELOT (Comparison of Amlodipine vs. Enalapril
to Limit Occurrences of Thrombosis) study also failed to show an
advantage of ACE inhibition over the comparator, a calcium
channel blocker (CCB) in patients with angiographically proven
coronary disease (6). Finally, meta-analyses of hypertension trials
have consistently failed to show an advantage of ACE inhibitor-
based therapy over other classes of BP lowering therapy in the
prevention of MI (1).
I concede that on the basis of our recent data from the CAFE
(Conduit Artery Function Evaluation) study, it is possible to go
beyond brachial BP, depending on the choice of the BP-lowering
agent (7). In the CAFE study we showed that beta-blocker 
thiazide-based therapy was less effective at lowering central aortic
pressure when compared to a CCB  ACE inhibitor-based
treatment, despite similar effects on brachial BPs. Thus, it is
plausible that brachial BP measurements underestimated the benefi-
cial effects of ACE inhibition on central aortic BPs in the HOPE
and EUROPA trials. However, even then it is still pressure and
hemodynamics and not mysterious biology that explain the benefit
of the drugs in these trials.
It is surely beyond dispute that the most effective way to “go
beyond blood pressure” to prevent MI in patients with hyperten-
sion at high risk of cardiovascular disease is to add a statin to their
therapy (1). No amount of ACE inhibition will compete with this,
no matter what clothes the emperor wears—indeed, on the basis of
evidence alone, with regard to ACE inhibition and the prevention
of MI by drug-specific effects, the emperor has no clothes!
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Keeping Apples and
Oranges Separate: Reassessing
Clinical Trials That Use Composite
End Points as Their Primary Outcome
It has become increasingly common for clinical trials in cardiovas-
cular medicine to use composite primary end points that often have
varying clinical importance. Time-to-event analyses, in which
mortality is but one of several outcomes, are particularly problem-
atic as the impact of death is clearly not equivalent to other
nonfatal outcomes such as rehospitalization (1). Another concern
is that indiscriminately combining mortality with other outcomes
in survival analyses may lead to biases related to “competing
risk” (2). Specifically, patients dying early in a clinical trial are
unable to experience future nonfatal outcomes.
To overcome these concerns, Cleland et al. (3) have used a novel
approach that relies on a composite outcome, namely “days lost due
to death or hospitalization,” over their eight-month follow-up
period. (They also separately reported one-year all-cause mortal-
ity.) By developing this composite outcome, the investigators have
avoided directly equating rehospitalization with death as in a
traditional event-free survival analysis, while at the same time
allowing for patients to have repeated rehospitalizations. This
approach allows clinicians to better appreciate the effect of home
telemonitoring on their composite end point and its overall clinical
and economic consequences.
Because of recent advances in cardiovascular medicine and lower
short-term mortality rates, it has become necessary for many
clinical trials to incorporate composite end points into their
protocols as a primary outcome in order to demonstrate biological
efficacy and statistical significance (1,2). We applaud Cleland
et al. (3) for using an innovative and rational composite end point
to evaluate a clinically relevant outcome in high-risk patients with
heart failure. Their meticulous reporting of each component of their
composite end point is also important and should be commended.
Of course, we wonder whether additional methodologies such
as “weighting” individual components of a composite end point—
days dead are counted more heavily than days hospitalized, for
example—may further improve these approaches. Such a strategy
of weighting outcomes was used effectively in the recent A-HeFT
(African-American Heart Failure Trial) study (4). Perhaps at a
minimum, separate reporting of individual components of a
composite primary end point should become routine and even
integrated into the CONSORT (Consolidated Standards of Re-
porting Trials) guidelines (1).
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Noninvasive Home Telemonitoring:
The Trans-European Network–
Home-Care Management System
Cleland et al. (1) for the first time demonstrated that telemedical
support in the follow-up of ambulatory patients with chronic heart
failure (CHF) compared to usual care is associated with survival
benefits as well as reduced length of hospitalization. The greatest
financial burden of CHF for society is associated with its high
hospitalization rates. Cleland et al. showed that hospitalization
rates were reduced in the group of patients receiving telemedical
care, but not in patients receiving nurse-led care. Their study sets
a new standard in telemedical research. The introduction of future
technology will not be possible without investigating the effects on
morbidity and mortality.
During the last five years, three generations of telemedical
systems have been introduced. The first-generation system was
based on sensors typically employing conventional telephone
systems to transfer data into central databases, which was then—
without analysis—transferred to physicians. The second-
generation system involved the use of additional sensors, but the
main difference was in the additional processing of the incoming
data. The system employed in the study by Cleland et al. (1)
represents this approach. The main structural problems of these
systems are the divided responsibility in all decision-making
processes and that direct patient contact is not utilized. Hence,
their medical impact is indirect and delayed.
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